| URL | https://www.fiercepharma.com/manufacturing/cdmo-vi |
| Source | Fierce Pharma |
| Date Published | 06/10/2021 |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Company/Division name | Vibalogics |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2021 |
| Capital investment ($): | 150 |
| Country(ies) from which reshored: | Germany |
| City reshored to: | Boxborough |
| State(s) reshored to: | MA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | oncolytic viruses and viral vectors |
| What domestic positive factors made reshoring more attractive? | , covid-19 |